Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention.

about

Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention.

Item

http://www.wikidata.org/entity/Q39066781

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@en

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@nl

type

Item

label

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@en

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@nl

prefLabel

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@en

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@nl

P1476

Optimizing the use of oral ant ...... a pharmacist-led intervention.

@en

P2093

Mandeep S Virdee

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence based medicine: a movement in crisis?

Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention

Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial

A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Dabigatran versus warfarin in patients with atrial fibrillation

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

P2888

s11096-016-0419-x

P304

173-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11096-016-0419-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Derek Stewart

P577

2017-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28050712

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation